الفهرس 
Introduction & the aim of the workOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular carcinoma. The current treatment regimen with ribavirin in combination therapy can produce sustained viral response. During treatment with ribavirin therapy, patients were identified as having haematological abnormalities whether they had anaemia, neutropenia, thrombocytopenia, or a combination of the above.
This study aimed to investigate the association between ITPase activity and haematological side effects occurring during DAA/RBV-based therapy in patients with HCV-related cirrhosis.
Results:
A total of 50 patients were treated for chronic HCV infection with dual therapy contained RBV from whom sera samples were available for genetic testing. Patients were divided into 50% males and 50% females with age ranged between 21 to 63 years and the body weight ranged between (60-130 kg).
Patients were included in the study if they received at least one dose of ribavirin through 3 months of treatment. The dose was administered orally from 800 to 1,200 mg of ribavirin based on the patient body weight.
Liver function tests, CBC were measured.The activity of the ITPA gene was determined by real-time PCR. Agarose gel electrophoresis was performed for PCR product.
Conclusion:
The reduction of ITPA gene expression increases the likelihood of developing hemolytic anaemia for HCV-infected patients on RBV-based therapy.